Healthify merges with US nutrition-care platform Berry Street in all-stock deal

Bengaluru-based Healthify has merged with Berry Street, combining its AI health platform with Berry Street’s insurance-backed network of more than 2,000 clinicians across all 50 US states. The combined company will use the Healthify brand in India and international markets.

— Source publishedMon, 24 Aug, 2026, 19:44 IST·First seen Mon, 24 Aug, 2026, 19:46 IST·Source Entrackr · Newsletter

What happened

Bengaluru-based Healthify merged with US nutrition-care company Berry Street in an all-stock deal, combining Healthify’s AI health platform with Berry Street’s

Key facts

  • All-stock deal
  • More than 2,000 clinicians
  • 50 US states
  • Founded in 2012
  • Around $150 million raised

Why this matters

The deal illustrates how health-tech platforms can use clinician-network acquisitions to accelerate US market entry, reimbursement access, and care-delivery capabilities without building regulated infrastructure from scratch.

What to watch

  • New or expanded US payer, employer or health-system contracts.
  • Evidence that Healthify features are embedded in Berry Street's clinician workflow rather than offered as a separate app.
  • Changes in Berry Street clinician count, patient volumes, reimbursement rates and dietitian utilization.
  • US regulatory, HIPAA, data-localization and AI clinical-decision-support disclosures.
  • Partnerships with GLP-1 prescribers, pharmacies, diabetes-care vendors or obesity-management platforms.
  • Follow-on funding, valuation signals or a US operating headquarters announcement.
  • Launch Healthify AI tools for Berry Street clinicians and patients, with US privacy and clinical-governance controls.
  • Use Berry Street's payer credentials to pursue reimbursement contracts for obesity, diabetes, PCOS and GLP-1 nutrition-support programs.
  • Package dietitian access with Healthify's consumer engagement products for employers and health plans.
  • Maintain distinct India/international branding while deciding whether Berry Street's US brand should remain customer-facing.
  • Prioritize outcomes studies showing engagement, adherence, clinician capacity gains and medical-cost impact.